A major advance in ACT has been the ability to rapidly generate large numbers of genetically redirected T cells that target specific tumor antigens using peripheral blood lymphocytes. One approach is the insertion of recombinant T cell receptors (TcRs). (8, 9) Another approach has been the creation of "chimeric antibody receptors" (CARs). (10) CARs are cell surface molecules in which the V H and V L regions of a monoclonal antibody are expressed as a single-chain variable fragment (scFv) and linked to the signal transduction domain of the CD3-zeta chain. More recent versions to achieve optimal T cell activation. (11, 12) Our group has focused on introducing CARs using lentiviral vectors (13) and has initiated a clinical trial using this technology.
Although ACT appears to be one of the most robust forms of immunotherapy for the treatment of tumors, the strategy requires further optimization to overcome some significant hurdles. (11, 12) An overarching issue is safety, especially in light of lethal toxicities in recent attempts at applying ACT strategy clinically (reviewed in (14) ).
However, there are also a number of issues related to increasing the efficacy of the cell receptors or CARs, a reasonable hypothesis is that additional modifications to change chemokine receptor expression could be advantageous.
Our group is developing ACT employing T cells transduced with lentiviral vectors encoding a chimeric antibody receptor recognizing the protein mesothelin (mesoCAR T cells). Mesothelin is a surface protein that is expressed at low levels on serosal cells (i.e. on the pleura, pericardium, peritoneum, tunica vaginalis), but is highly expressed on a number of malignancies, including malignant pleural mesothelioma (MPM), ovarian cancer and pancreatic cancer (23, 24) . Due to the restricted, low basal levels of expression on non-malignant tissue, and the ubiquitous over-expression on various tumor types, mesothelin appears to be an attractive tumor antigen target. Clinical trials are underway using unmodified or exotoxin-conjugated anti-mesothelin antibodies and have demonstrated safety and some efficacy. (25) (26) (27) We have recently demonstrated anti-tumor activity of adoptively transferred mesoCAR T cells in preclinical mouse models of MPM (28, 29) and have initiated a pilot and feasibility clinical trial using mesoCAR T cells for patients with MPM. The hypothesis for this study is that optimization of this approach requires the CCR repertoire on the injected activated mesoCAR T cells to be "matched" to the chemokines most abundantly secreted by MPM tumors. Accordingly, we determined: 1) which chemokines are consistently secreted at high levels by MPM tumor cells, 2) which CCRs are expressed in T cells activated using clinically compliant conditions, 3) if introduction of an appropriate "matching" CCR into T cells augments trafficking to tumor, 4) and if enhanced trafficking translates into improved anti-tumor efficacy. Given the clinical prospects of treating MPM patients with extensive disease, our priority was to address these issues Assay. Supernatants or malignant pleural fluid samples from subjects with MPM were analyzed by ELISA for cytokine measurements using the manufacturer's instructions.
Evaluating resting and activated T cell chemokine receptor (CCR) expression:
CCR expression was measured by FACS in resting peripheral blood mononuclear cells (PBMCs) acquired from the University of Pennsylvania's Human Immunology Core.
Purified PBMC T cells were activated by magnetic beads coated with anti-CD3/anti-CD28 (protocol details outlined elsewhere (28) ). TILs were acquired from malignant MPM pleural effusion samples or MPM surgical biopsies, and activated with high dose IL-2 (Novartis, Basel, Switzerland) (protocol details outlined elsewhere (4)). 
Results:
Chemokine production by MPM tumors.
Our first goal was to assess which chemokines were produced consistently and at elevated levels by MPM tumors. Cell culture supernatants from 11 human MPM cell lines were analyzed by a multiplex cytokine assay. Of the 20 chemokines and cytokines examined, CCL2 was one of the most highly and uniformly expressed. Confirmation using an ELISA, showed that the mean concentration of CCL2 was 3500 ± 2210 pg/ml/10 6 cells/24 hrs, with 6 of the 11 lines secreting more than 500 pg/ml/10 (Table 1 , bottom panel). Serum levels were overall much lower.
Chemokine receptor expression on resting and activated T cells.
We next analyzed which CCRs were expressed on activated T cells, with special attention to the receptor that binds to CCL2 (CCR2). Because different in vitro activation protocols can result in different CCR profiles (see discussion), we compared expression levels on resting T cells from PBMCs, MPM TILs activated by high IL-2 supplementation (600IU/ml), and bead-activated peripheral blood T cells (the method we are using in our clinical trials). FACS was performed by gating on CD4 or CD8 positive lymphocytes (Table 2) . Consistent with the literature (36) (37) (38) , the most highly expressed CCR was CXCR3 (which binds CXCL9, 10, and 11), with expression as high as 83% of the bead-activated cells. In contrast, CCR2 was uniformly expressed at low 
CCR2b can be successfully transduced into activated T cells.
In light of the high CCL2 secretion by the MPM tumors but low CCR2 expression on the activated T cells, we hypothesized that T cell trafficking to MPM could be augmented by genetically engineering T cells to express CCR2. Because CCR2b is the most dominant isoform of this receptor (39), a codon-optimized construct of CCR2b was generated and packaged into a lentivirus vector. Lentiviral vector transduction of T cells undergoing anti-CD3/anti-CD28 bead-activation was achieved using the lentiviral vector for mesoCAR alone or transduction using both mesoCAR and CCR2b lentiviral vectors.
Compared to untransduced cells (Fig. 1, left panel) , single mesoCAR transduction resulted in expression in ~30% of cells (Fig. 1, middle panel) . FACS analysis post-transduction with both vectors revealed that ~12% of T cells expressed mesoCAR only, ~23% of cells expressed CCR2b only, and ~19% of T cells had robust expression of both mesoCAR and CCR2b (Fig. 1, right panel) .
Functional Activity of Transduced CCR2b in activated T cells.
Since CCR engagement by ligand induces an increase in intracellular calcium shown in Figure 2A , addition of 100ng/ml CCL2 (arrow) to untransduced T cells did not induce a calcium influx, whereas the subsequent addition of the calcum ionophore, ionomycin, (arrowhead), resulted in a large increase in the fluorescence ratio indicating calcium influx. In contrast, as shown in Figure 2B , addition of 100ng/ml CCL2 (arrow) to CCR2b T cells resulted in a clear calcium spike (arrow), as did the subsequent addition of ionomycin (arrowhead), demonstrating that the introduced CCR2b exhibited physiological signal transduction in T cells.
The chemotactic function of the transduced CCR2b was also tested. Figure 2C shows the results from transwell studies in which transduced or untransduced T cells were allowed to migrate through a 0.5um polycarbonate membrane towards media alone or media containing 100ng/ml CCL2 in the lower well. Whereas CCL2 only increased the migration rate of mesoCAR T cells by 0.7 ± 2.7% compared to media alone, CCL2 induced a 45 ± 4.4% increase in migration of mesoCAR + CCR2b T cells compared to media alone (p<0.001), indicating a robust functional enhancement of the CCR2b modified T cells.
The assay was repeated to evaluate migration of CCR2b T cells towards M108-conditioned supernatant (Fig. 2D ). Relative to transwell migration of CCR2b T cells towards R10, supernatant from M108 induced over a 100% increase in transwell migration. Anti-CCL2 antibody caused complete inhibition of supernatant-induced migration, confirming the effect as being CCL2 dependent.
Effect of CCR2b transduction on T cell in vitro killing of M108
We next explored the susceptibility of M108 to mesoCAR and mesoCAR + CCR2b T cell-mediated lysis using in vitro killing assays. As shown in Figure 3 we added mesoCAR T cells to luciferase-labeled tumor cells at a constant ratio of 20 lymphocytes to one tumor cell and determined the number of live tumor cells after 4 hours, the T cells were able to kill 35.5 ± 1.9% of M108 cells. Interestingly, mesoCAR + CCR2b T cells were able to kill ~20% more M108 cells than mesoCAR T cells (55.2 ± 1.6% vs. 35.5 ± 1.9%, p<0.01). Additionally, this effect was further augmented by ~13% when mesoCAR + CCR2b T cells were exposed to 100ng/ml of CCL2 during coculture (55.2 ± 1.6% vs. 68.3 ± 3.2%, p=0.02).
To address the question of whether interaction between CCL2 and CCR2b may non-specifically activate T cells (which in turn could lead to potential "on-target/offtumor" toxicity), we tested the ability of mesoCAR + CCR2b T cells to kill mesothelinexpressing versus non-mesothelin-expressing tumor targets in the presence of supplemental CCL2. As shown in Supp. Fig. 4 , without tumor expression of mesothelin, the mesoCAR + CCR2b T cells were not able to kill tumor cells, even in the presence of CCL2.
Effect of CCR2b transduction on T cell infiltration in NSG mice with M108 flank tumors.
We next tested the ability of each type of activated T cell to traffic into Blood acquired via retroorbital bleeding from the three sacrificed animals was pooled and also subjected to FACS analysis (Fig. 4B) . Mice in the untransduced group had 114,100 circulating T cells per million total cells and mice in the mesoCAR T cell group had 103,600 circulating T cells per million total cells. However, mice in the mesoCAR + CCR2b T cell group had only 36,500 circulating T cells per million total cells. We interpret this to indicate that the increased TILs seen in the mesoCAR + CCR2b group tumors were due to enhanced trafficking and not enhanced systemic proliferation.
Research. 
Effect of CCR2b transduction on antigen-independent T cell trafficking to CCL2 secreting flank tumors.
Although these data definitively show increased numbers of T cells within the tumors at Day 5, it is difficult to say whether the increased numbers of T cells within the tumor were due to: 1) increased trafficking, 2) decreased apoptosis, 3) increased proliferation, or 4) increased retention in the tumor after the initial entry.
To explore these possibilities, we labeled T cells or CCR2b bearing T cells with firefly luciferase (ffluc) and compared the ability of these cells to home to MPM tumor that made large amounts of CCL2, but did not express mesothelin (the MSTO cell line).
As shown in Figure 4D , by 24 hours, both types of T cells initially trafficked to the liver, but as early as 24 hours after injection, the CCR2b T cell injected mouse revealed T cells in the flank tumor, which continued to accumulate to a larger degree than in the control mouse. By the 3 rd day, the control mouse had no T cells in the flank tumor, whereas some accumulation could be detected in the mouse injected with CCR2b T cells. By Day 6, no T cells were detectable in either mouse by imaging. Since no antigen was provided and thus no T cell proliferation was induced, this study clearly shows increased trafficking of the CCR2b T cells to the tumor.
Effect of CCR2b transduction on anti-tumor activity in NSG mice with M108 flank tumors.
In the same experiment described above (NSG, flank M108), we also observed significant differences in tumor growth over time (Fig. 4C) . The tumors in the control and untransduced T cell groups grew steadily at similar rates, reaching a size of 
Discussion
This study showed that it was possible to increase the number of adoptively transferred T cells within large, well-established, mesothelin-expressing tumors by matching the chemokine receptors expressed on the activated T-cells with the chemokines secreted by the tumor. This was accompanied by significantly enhanced anti-tumor efficacy, even in large, established tumors.
Our study clearly showed increased numbers of CCR2b-expressing T cells within the tumor at 5 days, however, it is very difficult to say for certain whether the increased numbers of T cells within the tumor were due to: 1) increased trafficking, 2) decreased apoptosis, 3) increased proliferation, or 4) increased retention in the tumor after the initial entry. Although it is likely that all factors played a role, we do have some imaging data with a tumor that does not express mesothelin (and thus is unlikely to stimulate antigen-induced proliferation) demonstrating increased trafficking of the CCR2b-expressing cells (Fig. 4D) There may also be a number of important safety advantages to tumor targeting.
Focusing T cell activity to tumors could allow lower doses to be administered, thus increasing the therapeutic index, since the CAR cells will traffic to tumor instead of being distributed in the periphery where they could have deleterious "on-target/offtumor" effects. This can be seen in Figure 4B , where CCR2b T cells were found in much lower number in the blood than the T cells lacking CCR2b. Minimizing "ontarget/off-tumor" effects remains an important goal in light of case reports of fatalities resulting from CAR T cell treatment toxicity (reviewed in (14)). In the example of mesothelin-targeted T cells, normal pericardial and peritoneal tissues express mesothelin, albeit at lower levels than tumor, and could be potential sources of toxicity.
Finally, it is possible that improving T cell trafficking to tumors, where substantial antigen-induced local proliferation could occur, could lessen, if not eliminate, the need for the aggressive lymphodepletion regimens that are now being employed. (42, 43) Lymphodepletion using chemotherapy (e.g. cyclophosphamide, fludarabine) and whole body irradiation presents substantial side-effect risks and markedly increases the costs of current trials. Of course, this hypothesis remains speculative and will need to be further tested in appropriate animal models (see below). 
increasing concentrations of IL2 in the T cell medium leads to upregulation of the CCR2 receptor. Brown et al. supplemented their T cell growth cultures with 25U/ml of IL2 whereas we did not.
The expression pattern of CCRs using costimulated T cells indicates that these T cells would mostly likely be attracted to tumors expressing the chemokines CCL5 (binding to CCR5) or CXCL9, CXCL10, or CXCL11 (binding to CXCR3). However, when we examined a large panel of mesothelioma cell lines and pleural fluids from patients with malignant mesothelioma, we found that there was very little secretion of these chemokines (data not shown). Instead we observed substantial amounts of CCL2 expressed by most (but not all) cell lines and patient specimens. The other chemokine produced by many of the cell lines was CXCL8 (interleukin 8) (data not shown). As the receptors for CXCL8 (CXCR1 and CXCR2) are not expressed on our T cells, we are also pursuing similar studies to introduce CXCR1 into T cells.
By introducing the properly matched CCR (i.e. CCR2b) into the T cells using a lentiviral vector, we were able to achieve dual expression of the CAR and the CCR in almost one quarter of the cells (Fig. 1) . This is similar to the results published by Di 
The concept of matching tumor-secreted chemokines with the appropriate CCR on the transfused, activated T cell, was first proposed by Kershaw et al. in 2002 (47) who conducted in vitro studies matching secretion of the chemokine Groα (CXCL1) by melanoma cells with a retrovirally-transduced CXCR2 receptor in IL-2-activated T cells. Although no model is perfect, we plan to use this "syngeneic system" to study important issues relating to lymphodepletion and the effects of a more normal tumor microenvironment.
One additional issue to consider would be sites other than MPM where CCR2 over-expressing T cells might accumulate, as this could determine potential toxicities.
CCL2 can be produced by many cell types, including endothelial, fibroblasts, epithelial, smooth muscle, mesangial, astrocytic, monocytic, and microglial cells. (58) (59) (60) (61) , however, we were unable to find literature describing high levels of CCL2 being present in tissues during non-diseased states. Thus, it appears that CCL2 may not be primarily involved in normal homeostasis, but rather in pathologic processes (62) . However, high levels of CCL2 have been reported in inflammatory diseases (e.g. rheumatoid arthritis, atherosclerosis (60, 63) ), wound healing (64, 65) , and malignant diseases (e.g. breast cancer, bladder cancer, gastric cancer (66) (67) (68) ). With regard to our mesoCAR + CCR2b T cells, it is thus possible that they could be recruited to sites of wound healing or inflammation, as well as to tumors. However, because of their very restricted antigen reactivity, they would only be potentially activated in the limited number of tissues expressing mesothelin at baseline (i.e. peritoneum, pericardium, tunica 
